Histopathological Difficulties in an Adolescent Lymphoma Patient

Ferenc Magyari, Sándor Barna, Zsófia Miltényi, Hajnalka Rajnai, Judit Csomor, M. Udvardy, A. Illés, László Váróczy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The B-cell lymphoma, unclassifiable, showing intermediate features typical for both diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (HL) is a novel category of diffuse large B-cell lymphomas (DLBCL/HL), which has been described by the WHO classification in 2008. This rare type of lymphomas, previously called as gray zone lymphoma presents peculiar clinical, morphological and immunophenotypical patterns. In December 2011 a 17-year old male was diagnosed with mixed cellularity subtype of classical HL. His clinical stage was IV/BXS (abdominal bulky) with unfavourable prognosis. Because of the unusally extended disease (nodal-extranodal-bulky) a histological revision was performed. After an incomplete course of ABVD chemotherapy the patient’s symptoms disappeared and regression was detected in the size of peripheral lymph nodes. The diagnosis changed into DLBCL/HL, so the treatment was modified to R-CHOP-14 regimen. After the administration of 3 cycles of R-CHOP-14, he achieved a complete metabolic remission (CMR), which was confirmed by a 18FDG-PET/CT scan. Receiving further 4 cycles of R-CHOP-14 therapy the patient was still in CMR, but a PET negative large mass (70 × 30 mm) still remained visible in the abdominal region. Considering this residuum and the agressive subtype of lymphoma he was referred for an autologous hemopoietic stem cell transplantation (AHSCT). After 2 cycles of R-DHAP regimen, successful CD34 positive stem cell collection was performed in August 2012. In September 2012, he underwent a R-BEAM conditioning followed by AHSCT. The next 18FDG-PET/CT still detected CMR 100 days after the AHSCT. The patient was in excellent clinical condition and also in complete remission 15 months after the AHSCT. Upon this case, it should be underlined that the diagnosis may need revision if a patient represents atypical clinical signs and behavior, and the importance of cooperation between clinicians and pathologists is also strongly emphasized.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalPathology and Oncology Research
Volume21
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Hodgkin Disease
Lymphoma
Fluorodeoxyglucose F18
B-Cell Lymphoma
Stem Cells
Lymph Nodes
Drug Therapy
Therapeutics

Keywords

  • 18FDG-PET/CT
  • Agressive lymphomas
  • B-cell lymphoma intermediate beetwen DLBCL and classical HL
  • R-CHOP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Magyari, F., Barna, S., Miltényi, Z., Rajnai, H., Csomor, J., Udvardy, M., ... Váróczy, L. (2015). Histopathological Difficulties in an Adolescent Lymphoma Patient. Pathology and Oncology Research, 21(1), 213-217. https://doi.org/10.1007/s12253-014-9810-x

Histopathological Difficulties in an Adolescent Lymphoma Patient. / Magyari, Ferenc; Barna, Sándor; Miltényi, Zsófia; Rajnai, Hajnalka; Csomor, Judit; Udvardy, M.; Illés, A.; Váróczy, László.

In: Pathology and Oncology Research, Vol. 21, No. 1, 2015, p. 213-217.

Research output: Contribution to journalArticle

Magyari, F, Barna, S, Miltényi, Z, Rajnai, H, Csomor, J, Udvardy, M, Illés, A & Váróczy, L 2015, 'Histopathological Difficulties in an Adolescent Lymphoma Patient', Pathology and Oncology Research, vol. 21, no. 1, pp. 213-217. https://doi.org/10.1007/s12253-014-9810-x
Magyari, Ferenc ; Barna, Sándor ; Miltényi, Zsófia ; Rajnai, Hajnalka ; Csomor, Judit ; Udvardy, M. ; Illés, A. ; Váróczy, László. / Histopathological Difficulties in an Adolescent Lymphoma Patient. In: Pathology and Oncology Research. 2015 ; Vol. 21, No. 1. pp. 213-217.
@article{b549af57eca144d7821fbc84d624d8b0,
title = "Histopathological Difficulties in an Adolescent Lymphoma Patient",
abstract = "The B-cell lymphoma, unclassifiable, showing intermediate features typical for both diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (HL) is a novel category of diffuse large B-cell lymphomas (DLBCL/HL), which has been described by the WHO classification in 2008. This rare type of lymphomas, previously called as gray zone lymphoma presents peculiar clinical, morphological and immunophenotypical patterns. In December 2011 a 17-year old male was diagnosed with mixed cellularity subtype of classical HL. His clinical stage was IV/BXS (abdominal bulky) with unfavourable prognosis. Because of the unusally extended disease (nodal-extranodal-bulky) a histological revision was performed. After an incomplete course of ABVD chemotherapy the patient’s symptoms disappeared and regression was detected in the size of peripheral lymph nodes. The diagnosis changed into DLBCL/HL, so the treatment was modified to R-CHOP-14 regimen. After the administration of 3 cycles of R-CHOP-14, he achieved a complete metabolic remission (CMR), which was confirmed by a 18FDG-PET/CT scan. Receiving further 4 cycles of R-CHOP-14 therapy the patient was still in CMR, but a PET negative large mass (70 × 30 mm) still remained visible in the abdominal region. Considering this residuum and the agressive subtype of lymphoma he was referred for an autologous hemopoietic stem cell transplantation (AHSCT). After 2 cycles of R-DHAP regimen, successful CD34 positive stem cell collection was performed in August 2012. In September 2012, he underwent a R-BEAM conditioning followed by AHSCT. The next 18FDG-PET/CT still detected CMR 100 days after the AHSCT. The patient was in excellent clinical condition and also in complete remission 15 months after the AHSCT. Upon this case, it should be underlined that the diagnosis may need revision if a patient represents atypical clinical signs and behavior, and the importance of cooperation between clinicians and pathologists is also strongly emphasized.",
keywords = "18FDG-PET/CT, Agressive lymphomas, B-cell lymphoma intermediate beetwen DLBCL and classical HL, R-CHOP",
author = "Ferenc Magyari and S{\'a}ndor Barna and Zs{\'o}fia Milt{\'e}nyi and Hajnalka Rajnai and Judit Csomor and M. Udvardy and A. Ill{\'e}s and L{\'a}szl{\'o} V{\'a}r{\'o}czy",
year = "2015",
doi = "10.1007/s12253-014-9810-x",
language = "English",
volume = "21",
pages = "213--217",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Histopathological Difficulties in an Adolescent Lymphoma Patient

AU - Magyari, Ferenc

AU - Barna, Sándor

AU - Miltényi, Zsófia

AU - Rajnai, Hajnalka

AU - Csomor, Judit

AU - Udvardy, M.

AU - Illés, A.

AU - Váróczy, László

PY - 2015

Y1 - 2015

N2 - The B-cell lymphoma, unclassifiable, showing intermediate features typical for both diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (HL) is a novel category of diffuse large B-cell lymphomas (DLBCL/HL), which has been described by the WHO classification in 2008. This rare type of lymphomas, previously called as gray zone lymphoma presents peculiar clinical, morphological and immunophenotypical patterns. In December 2011 a 17-year old male was diagnosed with mixed cellularity subtype of classical HL. His clinical stage was IV/BXS (abdominal bulky) with unfavourable prognosis. Because of the unusally extended disease (nodal-extranodal-bulky) a histological revision was performed. After an incomplete course of ABVD chemotherapy the patient’s symptoms disappeared and regression was detected in the size of peripheral lymph nodes. The diagnosis changed into DLBCL/HL, so the treatment was modified to R-CHOP-14 regimen. After the administration of 3 cycles of R-CHOP-14, he achieved a complete metabolic remission (CMR), which was confirmed by a 18FDG-PET/CT scan. Receiving further 4 cycles of R-CHOP-14 therapy the patient was still in CMR, but a PET negative large mass (70 × 30 mm) still remained visible in the abdominal region. Considering this residuum and the agressive subtype of lymphoma he was referred for an autologous hemopoietic stem cell transplantation (AHSCT). After 2 cycles of R-DHAP regimen, successful CD34 positive stem cell collection was performed in August 2012. In September 2012, he underwent a R-BEAM conditioning followed by AHSCT. The next 18FDG-PET/CT still detected CMR 100 days after the AHSCT. The patient was in excellent clinical condition and also in complete remission 15 months after the AHSCT. Upon this case, it should be underlined that the diagnosis may need revision if a patient represents atypical clinical signs and behavior, and the importance of cooperation between clinicians and pathologists is also strongly emphasized.

AB - The B-cell lymphoma, unclassifiable, showing intermediate features typical for both diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (HL) is a novel category of diffuse large B-cell lymphomas (DLBCL/HL), which has been described by the WHO classification in 2008. This rare type of lymphomas, previously called as gray zone lymphoma presents peculiar clinical, morphological and immunophenotypical patterns. In December 2011 a 17-year old male was diagnosed with mixed cellularity subtype of classical HL. His clinical stage was IV/BXS (abdominal bulky) with unfavourable prognosis. Because of the unusally extended disease (nodal-extranodal-bulky) a histological revision was performed. After an incomplete course of ABVD chemotherapy the patient’s symptoms disappeared and regression was detected in the size of peripheral lymph nodes. The diagnosis changed into DLBCL/HL, so the treatment was modified to R-CHOP-14 regimen. After the administration of 3 cycles of R-CHOP-14, he achieved a complete metabolic remission (CMR), which was confirmed by a 18FDG-PET/CT scan. Receiving further 4 cycles of R-CHOP-14 therapy the patient was still in CMR, but a PET negative large mass (70 × 30 mm) still remained visible in the abdominal region. Considering this residuum and the agressive subtype of lymphoma he was referred for an autologous hemopoietic stem cell transplantation (AHSCT). After 2 cycles of R-DHAP regimen, successful CD34 positive stem cell collection was performed in August 2012. In September 2012, he underwent a R-BEAM conditioning followed by AHSCT. The next 18FDG-PET/CT still detected CMR 100 days after the AHSCT. The patient was in excellent clinical condition and also in complete remission 15 months after the AHSCT. Upon this case, it should be underlined that the diagnosis may need revision if a patient represents atypical clinical signs and behavior, and the importance of cooperation between clinicians and pathologists is also strongly emphasized.

KW - 18FDG-PET/CT

KW - Agressive lymphomas

KW - B-cell lymphoma intermediate beetwen DLBCL and classical HL

KW - R-CHOP

UR - http://www.scopus.com/inward/record.url?scp=84939880671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939880671&partnerID=8YFLogxK

U2 - 10.1007/s12253-014-9810-x

DO - 10.1007/s12253-014-9810-x

M3 - Article

C2 - 24985032

AN - SCOPUS:84939880671

VL - 21

SP - 213

EP - 217

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -